Rothschild Investment LLC Buys 79 Shares of Agilent Technologies, Inc. (NYSE:A)

Rothschild Investment LLC grew its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 19.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 491 shares of the medical research company’s stock after buying an additional 79 shares during the quarter. Rothschild Investment LLC’s holdings in Agilent Technologies were worth $66,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of A. AMF Tjanstepension AB acquired a new position in shares of Agilent Technologies during the third quarter worth $2,726,000. International Assets Investment Management LLC acquired a new position in shares of Agilent Technologies during the third quarter worth $12,961,000. Assenagon Asset Management S.A. lifted its holdings in shares of Agilent Technologies by 173.6% during the third quarter. Assenagon Asset Management S.A. now owns 27,113 shares of the medical research company’s stock worth $4,026,000 after purchasing an additional 17,203 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Agilent Technologies by 18.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,388 shares of the medical research company’s stock worth $3,907,000 after purchasing an additional 4,118 shares during the period. Finally, PFG Investments LLC lifted its holdings in shares of Agilent Technologies by 6.9% during the third quarter. PFG Investments LLC now owns 2,345 shares of the medical research company’s stock worth $348,000 after purchasing an additional 152 shares during the period.

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Agilent Technologies Price Performance

Shares of NYSE A opened at $134.51 on Thursday. The firm’s 50-day moving average price is $140.90 and its 200-day moving average price is $139.28. Agilent Technologies, Inc. has a 1-year low of $124.16 and a 1-year high of $155.35. The firm has a market capitalization of $38.37 billion, a P/E ratio of 30.43, a P/E/G ratio of 3.66 and a beta of 1.07. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The firm had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion. Equities research analysts anticipate that Agilent Technologies, Inc. will post 5.56 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies’s payout ratio is presently 22.40%.

Wall Street Analyst Weigh In

A has been the topic of a number of recent research reports. Bank of America cut their price target on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and lifted their price target for the stock from $135.00 to $145.00 in a report on Monday, February 10th. Sanford C. Bernstein cut their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Finally, Citigroup boosted their target price on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday, December 19th. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $144.38.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.